Ray Dalio's PFE Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 180,092 shares of Pfizer Inc. (PFE) worth $4.34 M, representing 0.02% of the portfolio. First purchased in 2013-Q3, this long-term strategic position has been held for 43 quarters.
Based on 13F filings since 2013, Ray Dalio has maintained a long-term strategic position in PFE, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2022, adding 2.58 M shares. Largest reduction occurred in Q1 2024, reducing 1.21 M shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Pfizer (PFE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Pfizer (PFE) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +180,092 | New Buy | 180,092 | $24.08 |
| Q3 2025 | -1.01 M | Sold Out | 0 | $0.00 |
| Q2 2025 | -640,790 | Reduce 38.75% | 1.01 M | $24.24 |
| Q1 2025 | +1.38 M | Add 503.84% | 1.65 M | $25.34 |
| Q4 2024 | +261,992 | Add 2211.46% | 273,839 | $26.53 |
| Q3 2024 | -23,580 | Reduce 66.56% | 11,847 | $28.94 |
| Q2 2024 | -40,179 | Reduce 53.14% | 35,427 | $27.98 |
| Q1 2024 | -1.21 M | Reduce 94.10% | 75,606 | $27.75 |
| Q4 2023 | -338,136 | Reduce 20.88% | 1.28 M | $28.79 |
| Q3 2023 | -166,015 | Reduce 9.30% | 1.62 M | $33.17 |
| Q2 2023 | +110,564 | Add 6.60% | 1.79 M | $36.68 |
| Q1 2023 | -1.06 M | Reduce 38.79% | 1.68 M | $40.80 |
| Q4 2022 | -101,884 | Reduce 3.59% | 2.74 M | $51.24 |
| Q3 2022 | -179,203 | Reduce 5.94% | 2.84 M | $43.76 |
| Q2 2022 | -296,380 | Reduce 8.94% | 3.02 M | $52.43 |
| Q1 2022 | +2.58 M | Add 352.33% | 3.31 M | $51.77 |
| Q4 2021 | +567,368 | Add 343.23% | 732,671 | $59.05 |
| Q3 2021 | +3,978 | Add 2.47% | 165,303 | $43.01 |
| Q2 2021 | +153,839 | Add 2055.02% | 161,325 | $39.16 |
| Q1 2021 | +7,486 | New Buy | 7,486 | $36.20 |
| Q2 2020 | -84,142 | Sold Out | 0 | $0.00 |
| Q1 2020 | +84,142 | New Buy | 84,142 | $32.64 |
| Q4 2018 | -298,598 | Sold Out | 0 | $0.00 |
| Q3 2018 | -87,708 | Reduce 22.70% | 298,598 | $44.07 |
| Q2 2018 | +191,984 | Add 98.80% | 386,306 | $36.28 |
| Q1 2018 | +194,322 | New Buy | 194,322 | $35.49 |
| Q3 2017 | -183,203 | Sold Out | 0 | $0.00 |
| Q2 2017 | +121,108 | Add 195.04% | 183,203 | $33.59 |
| Q1 2017 | -220,105 | Reduce 78.00% | 62,095 | $34.21 |
| Q4 2016 | -344,139 | Reduce 54.94% | 282,200 | $32.48 |
| Q3 2016 | +65,700 | Add 11.72% | 626,339 | $33.87 |
| Q2 2016 | +100,600 | Add 21.87% | 560,639 | $35.21 |
| Q1 2016 | +25,631 | Add 5.90% | 460,039 | $29.64 |
| Q4 2015 | +88,700 | Add 25.66% | 434,408 | $32.28 |
| Q3 2015 | +266,600 | Add 337.01% | 345,708 | $31.41 |
| Q2 2015 | +79,108 | New Buy | 79,108 | $33.52 |
| Q1 2015 | -211,208 | Sold Out | 0 | $0.00 |
| Q4 2014 | -83,900 | Reduce 28.43% | 211,208 | $31.15 |
| Q3 2014 | -97,900 | Reduce 24.91% | 295,108 | $29.57 |
| Q2 2014 | +280,900 | Add 250.56% | 393,008 | $29.68 |
| Q1 2014 | +1,700 | Add 1.54% | 112,108 | $32.12 |
| Q4 2013 | +55,800 | Add 102.18% | 110,408 | $30.63 |
| Q3 2013 | +54,608 | New Buy | 54,608 | $28.73 |
Ray Dalio's Pfizer Investment FAQs
Ray Dalio first purchased Pfizer Inc. (PFE) in Q3 2013, acquiring 54,608 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Pfizer Inc. (PFE) for 43 quarters since Q3 2013.
Ray Dalio's largest addition to Pfizer Inc. (PFE) was in Q1 2022, adding 3,314,055 shares worth $171.57 M.
According to the latest 13F filing for Q2 2026, Ray Dalio's firm, Bridgewater Associates, Lp, owns 180,092 shares of Pfizer Inc. (PFE), valued at approximately $4.34 M.
As of the Q2 2026 filing, Pfizer Inc. (PFE) represents approximately 0.02% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Pfizer Inc. (PFE) was 3,314,055 shares, as reported at the end of Q1 2022.